| Literature DB >> 30615903 |
Benjamin Dannenmann1, Azadeh Zahabi1, Perihan Mir2, Benedikt Oswald1, Regine Bernhard1, Maksim Klimiankou1, Tatsuya Morishima1, Klaus Schulze-Osthoff3, Cornelia Zeidler4, Lothar Kanz1, Nico Lachmann5, Thomas Moritz5, Karl Welte6, Julia Skokowa7.
Abstract
We describe the establishment of an embryoid-body-based protocol for hematopoietic/myeloid differentiation of human induced pluripotent stem cells that allows the generation of CD34+ cells or mature myeloid cells in vitro. Using this model, we were able to recapitulate the defective granulocytic differentiation in patients with severe congenital neutropenia (CN), an inherited preleukemia bone marrow failure syndrome. Importantly, in vitro maturation arrest of granulopoiesis was associated with an elevated unfolded protein response (UPR) and enhanced expression of the cell cycle inhibitor p21. Consistent with this, we found that CD34+ cells of CN patients were highly susceptible to DNA damage and showed diminished DNA repair. These observations suggest that targeting the UPR pathway or inhibiting DNA damage might protect hematopoietic cells of CN patients from leukemogenic transformation, at least to some extent.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30615903 DOI: 10.1016/j.exphem.2018.12.006
Source DB: PubMed Journal: Exp Hematol ISSN: 0301-472X Impact factor: 3.249